<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749241</url>
  </required_header>
  <id_info>
    <org_study_id>BL31929</org_study_id>
    <nct_id>NCT01749241</nct_id>
  </id_info>
  <brief_title>Efficacy of Loteprednol Ointment Following Eyelid Surgery</brief_title>
  <official_title>Loteprednol Etabonate Ophthalmic Ointment vs. Soothe Night Time Ointment for Inflammation Following Eyelid Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shiley Eye Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation occurs after any type of incisional surgery. This study will evaluate the
      efficacy of Loteprednol etabonate ointment vs. Soothe ointment (vehicle) for postoperative
      inflammation after routine eyelid surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eyelid surgery such as blepharoplasty is often performed for functional and cosmetic
      indications. Following any incisional surgery, postoperative inflammation occurs at the
      surgical site. This study will evaluate the efficacy of reducing postoperative inflammation
      after bilateral eyelid surgery using Loteprednol etabonate (steroid) vs. Soothe ointment
      (vehicle of Loteprednol etabonate). Common postoperative changes at the incision include:
      erythema, thickening/elevation of the skin, pigmentary changes and pain. The use of a
      topically applied steroid would be expected to reduce inflammation and this study will
      evaluate this. For each patient, one eyelid will be randomly chosen to treat with medication
      and the other eyelid will be treated with vehicle ointment and by using the same patient,
      each patient will be internally controlled. Antibiotic prophylaxis is often given after
      eyelid surgery and this will be used in all patients in the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>24 weeks after surgery</time_frame>
    <description>Inflammatory changes of the periocular skin will be assessed by several criteria including: 1. Erythema 2. Wound elevation 3. Pigmentary changes 4. Exudate 5. Excoriation 6. Crusting 7. Scaling 8. Pain 9. Itching</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Post-operative Healing Following Blepharoplasty and Ptosis Repair</condition>
  <arm_group>
    <arm_group_label>Loteprednol etabonate ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the arm which contains loteprednol steroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ointment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm contains vehicle only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate ophthalmic ointment</intervention_name>
    <description>Thin ribbon ointment to assigned eye twice daily for 14 days</description>
    <arm_group_label>Loteprednol etabonate ointment</arm_group_label>
    <other_name>Lotemax ophthalmic ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Ophthalmic Ointment</intervention_name>
    <description>Thin ribbon ointment to assigned eye twice daily for 14 days</description>
    <arm_group_label>Vehicle Ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Scheduled for bilateral eyelid surgery

          -  Willing and able to return for all study visits

          -  Willing and able to administer treatments as required

          -  Understand and sign informed consent approved by UCSD institutional review board

        Exclusion Criteria:

          -  History of allergy to investigational drug (Loteprednol etabonate) or ingredient in
             drug including petrolatum

          -  History of collagen vascular disease and receiving concurrent treatment that could
             interfere with interpretation of study results

          -  Concurrent ocular therapy with nonsteroidal anti-inflammatory drugs, mast cell
             stabilizers, antihistamines, decongestants, immunosuppresants, and systemic or ocular
             corticosteroids

          -  History of immunodeficiency

          -  Prior eyelid or facial surgery

          -  Prior ocular or orbital trauma

          -  History of ocular hypertension, steroid responder, or glaucoma

          -  Pregnancy or lactation

          -  Uncontrolled systemic disease or significant illness

          -  Any other condition the investigator believe would pose a significant hazard to the
             subject if the investigational therapy were initiated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bobby Korn, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD Med</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annaleah Ariola</last_name>
    <phone>858-534-7402</phone>
    <email>aariola@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bobby Korn, MD PhD</last_name>
    <phone>858-534-7402</phone>
    <email>bkorn@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shiley Eye Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Ledford, MBA</last_name>
      <phone>858-534-2109</phone>
      <email>cledford@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Chu</last_name>
      <phone>858-534-6866</phone>
      <email>cvchu@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bobby Korn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Don Kikkawa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Comstock TL, Paterno MR, Singh A, Erb T, Davis E. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol. 2011;5:177-86. doi: 10.2147/OPTH.S16832. Epub 2011 Feb 10.</citation>
    <PMID>21383946</PMID>
  </results_reference>
  <results_reference>
    <citation>A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmology. 1998 Sep;105(9):1780-6.</citation>
    <PMID>9754192</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Bobby Korn, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

